AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Plasma cell myeloma: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)NCT04939142 · results posted 2026-08-10 · Antengene Corporation · 154 people · tests SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)NCT04504825 · results posted 2026-07-02 · Alexion Pharmaceuticals, Inc. · 125 people · tests CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)NCT04512235 · results posted 2026-06-17 · Alexion Pharmaceuticals, Inc. · 281 people · tests CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial TherapyNCT03652064 · results posted 2026-04-08 · Janssen Research & Development, LLC · 395 people · tests Daratumumab, Bortezomib, Lenalidomide, Dexamethasone A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple MyelomaNCT03301220 · results posted 2025-12-23 · Janssen Research & Development, LLC · 390 people · tests Daratumumab SC: daratumumab + rHuPH20 SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMMNCT05405166 · results posted 2025-11-14 · Sanofi · 531 people · tests Isatuximab IV, Isatuximab SC, Dexamethasone, Pomalidomide
📚

In the leading journals

NEJM, Lancet, Nature, JCO, Cancer Cell and more · PubMed
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.Nature 2026 · PMID 42927884 Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 …Ann Oncol 2026 · PMID 42927858 From Diagnosis to Destruction: The Rise of Radioligand Therapeutics as Oncology's New Pillar.Ann Oncol 2026 · PMID 42927857 Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label…Ann Oncol 2026 · PMID 42927856 Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carc…Ann Oncol 2026 · PMID 42927855 Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE rando…Ann Oncol 2026 · PMID 42927854 A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: Re…Ann Oncol 2026 · PMID 42927853 Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer …Lancet Oncol 2026 · PMID 42927765 Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.Nat Med 2026 · PMID 42926233 Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 tria…Nat Med 2026 · PMID 42926136 Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.Ann Oncol 2026 · PMID 42926111 Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinas…Ann Oncol 2026 · PMID 42926110

Want these every week? Follow plasma cell myeloma and get a note on your phone with the new trials and papers.

🔔 Follow plasma cell myeloma
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy